[Controlled clinical trial of 4-prenyl-1,2-diphenyl-3,5-pyrazolidinedione (DA 2370) and oxyphenbutazone in thrombophlebitis].
D000328:Adult; D000368:Aged; D000893:Anti-Inflammatory Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001772:Blood Cell Count; D001806:Blood Urea Nitrogen; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010113:Oxyphenbutazone / Q000009:adverse effects / Q000627:therapeutic use*; D010146:Pain / Q000188:drug therapy; D011720:Pyrazoles / Q000009:adverse effects / Q000627:therapeutic use*; D012881:Skin Temperature / Q000187:drug effects; D013729:Terpenes / Q000009:adverse effects / Q000627:therapeutic use*; D013924:Thrombophlebitis / Q000188:drug therapy*; D000637:Transaminases / Q000097:blood
D000893:Anti-Inflammatory Agents; D011720:Pyrazoles; D013729:Terpenes; D000637:Transaminases; D010113:Oxyphenbutazone